BlueRock Therapeutics, a clinical stage cell therapy company, and bit.bio, the company coding human cells for novel cures, have announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs)...
New company Syena says it has the potential to create the next generation of cell therapy: combining the safety, potency and scalability of natural killer (NK) cells with the ability of T cell receptors (TCR) to target intracellular tumor antigens.
Servier to work with Yposeski for the production of lentiviral vectors, as the former works to develop allogenic CAR-T cell technology for hematological therapies.
US FDA grants orphan drug designation for Hyleukin-7, an immuno-oncology agent that boosts T cell production and functionality, for the treatment of ICL.
Celgene will add chimeric antigen receptor (CAR) and T-cell receptor (TCR) technologies through the acquisition of its immune-oncology partner Juno Therapeutics.
Adaptimmune has entered into a new 10-year development and supply agreement for use of thermos Fisher’s Dynabeads CD3/CD28 CTS T-cell isolation, activation and expansion technology.
GSK will develop and commercialise Adaptimmune’s T-cell receptor (TCR) cancer therapies in a deal that could yield more than $350m (€257m) for the Oxford, UK biopharma firm.
Adaptimmune has selected Biolife’s cryopreservation media for its genetically modified T-cell receptor (TCR) product citing its ability to retain viability and potency.